Zura Bio Q1 net loss $7.7M; cash $89.8M, closes $112.5M placement, appoints CEO

Zura Bio Ltd

2024-Q1 EPS reported -$0.02

Net loss $7.7M vs $9.6M prior year; cash $89.8M at March 31, 2024.
Closed oversubscribed $112.5M private placement in April 2024 from institutional investors.
Appointed Robert Lisicki as CEO and Kiran Nistala as CMO.
On track for Phase 2 trials: tibulizumab in SSc Q4 2024, HS Q2 2025.
Cash runway extended through 2027 with placement factored in.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Zura Bio Ltd reported first quarter 2024 results: net income $7.7 million.

Period: first quarter 2024
Net income: $7.7 million
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2024 was $7.7 million

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Zura Bio Ltd filing history →

Source: SEC EDGAR

accession 0001104659-24-059031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.